Skip to main content
Article thumbnail
Location of Repository

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

By P J Mease, P Ory, J T Sharp, C T Ritchlin, F Van den Bosch, F Wellborne, C Birbara, G T D Thomson, R J Perdok, J Medich, R L Wong and D D Gladman
Topics: Clinical and Epidemiological Research
Publisher: BMJ Publishing Group
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2003). A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis
  2. (2003). A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology
  3. (2007). Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum
  4. (2005). Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum
  5. (2007). Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis
  6. (2003). Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum
  7. (1995). Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model.
  8. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept.
  9. (2000). Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires inclinical trials ofrheumatoidarthritis. Arthritis Rheum
  10. Discussion: clinical features, epidemiology, classification criteria, and quality of life in psoriasis and psoriatic arthritis. Ann Rheum Dis 2005;64(Suppl 2)ii24–5.
  11. (1995). Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis? Clin Invest Med
  12. (1984). double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum
  13. (2004). Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis
  14. Employment across chronic inflammatory rheumatic diseases and comparison with the general population.
  15. How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials. Ann Rheum Dis 2004;63(Suppl 1):391.
  16. (2004). Long-term methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 1995;22:241–5. Extended report 708 Ann Rheum Dis 2009;68:702–709. doi:10.1136/ard.2008.09276712. Kaltwasser
  17. (1990). Longitudinal study of clinical and radiological progression in psoriatic arthritis.
  18. PASI 50 is a sensitive indicator of reduced radiographic progression in psoriatic arthritis patients treated with adalimumab (Humira): subanalysis of ADEPT. Ann Rheum Dis 2008;67(Suppl II):524.
  19. (2003). Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology
  20. (1991). Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients.
  21. (1987). Psoriatic arthritis (PSA): an analysis of 220 patients.
  22. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl 2):ii14–17.
  23. Psoriatic arthritis.
  24. (2002). Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol
  25. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889–94. Extended report Ann Rheum Dis 2009;68:702–709.
  26. The direct cost of care for psoriasis and psoriatic arthritis in the United States.
  27. The long-term use of azathioprine in patients with psoriatic arthritis.
  28. (1998). The use of sulfasalazine in psoriatic arthritis: a clinic experience.
  29. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean?
  30. Twoyear efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Controlled Trial (IMPACT).
  31. Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. JR h e u m a t o l1997;24:511–17.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.